Quantification of the adverse effect of ethinylestradiol containing oral contraceptive pills when used in conjunction with growth hormone replacement in routine practice

Clinical Endocrinology

Volumn 76, Issue 5, 2012, Pages 729-733

  Phelan, Niamh ^a   Conway, Sophy H ^a   Llahana, Sofia ^a   Conway, Gerard S ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ETHINYLESTRADIOL; HUMAN GROWTH HORMONE; ORAL CONTRACEPTIVE AGENT; SOMATOMEDIN C;

ADULT; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADOLESCENT; ADULT; BODY WEIGHT; CONTRACEPTIVES, ORAL; CONTRACEPTIVES, ORAL, COMBINED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, INTRADERMAL; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84859640805     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04277.x     Document Type: Article

References (25)

1. Salomon, F., Cuneo, R.C., Hesp, R. et al. (1989) The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. New England Journal of Medicine, 321, 1797-1803. (Pubitemid 20015573)
2. Maiter, D., Abs, R., Johannsson, G. et al. (2006) Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database. European Journal of Endocrinology, 155, 253-260. (Pubitemid 44269441)
3. Attanasio, A.F., Bates, P.C., Ho, K.K. et al. (2002) Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status-3-year results from the HypoCCS Database. Journal of Clinical Endocrinology and Metabolism, 87, 1600-1606. (Pubitemid 34618501)
4. Jorgensen, J.O., Pedersen, S.A., Thuesen, L. et al. (1989) Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet, 1, 1221-1225. (Pubitemid 19140325)
5. Widdowson, W.M. & Gibney, J. (2008) The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. Journal of Clinical Endocrinology and Metabolism, 93, 4413-4417. (Pubitemid 352789540)
6. Cenci, M.C., Soares, D.V., Spina, L.D. et al. (2009) Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency. Pituitary, 12, 322-329.
7. Conway, G.S., Szarras-Czapnik, M., Racz, K. et al. (2009) Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. European Journal of Endocrinology, 160, 899-907.
8. Boot, A.M., van der Sluis, I.M., Krenning, E.P. et al. (2009) Bone mineral density and body composition in adolescents with childhood- onset growth hormone deficiency. Hormone Research, 71, 364-371.
9. Rosilio, M., Blum, W.F., Edwards, D.J. et al. (2004) Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). Journal of Clinical Endocrinology and Metabolism, 89, 1684-1693. (Pubitemid 38514701)
10. Koltowska-Haggstrom, M., Mattsson, A.F. & Shalet, S.M. (2009) Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. European Journal of Endocrinology, 161(Suppl. 1), S51-S64.
11. Molitch, M.E., Clemmons, D.R., Malozowski, S. et al. (2011) Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 96, 1587-1609.
12. van den Berg, G., Veldhuis, J.D., Frolich, M. et al. (1996) An amplitude- specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. Journal of Clinical Endocrinology and Metabolism, 81, 2460-2467. (Pubitemid 26240261)
13. Burman, P., Johansson, A.G., Siegbahn, A. et al. (1997) Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. Journal of Clinical Endocrinology and Metabolism, 82, 550-555. (Pubitemid 27068627)
14. Leung, K.C., Johannsson, G., Leong, G.M. et al. (2004) Estrogen regulation of growth hormone action. Endocrine Reviews, 25, 693-721. (Pubitemid 39366048)
15. Wolthers, T., Hoffman, D.M., Nugent, A.G. et al. (2001) Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. American journal of physiology. Endocrinology and metabolism, 281, E1191-E1196. (Pubitemid 34001193)
16. Weissberger, A.J., Ho, K.K. & Lazarus, L. (1991) Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 72, 374-381. (Pubitemid 21921702)
17. Kelly, J.J., Rajkovic, I.A., O'Sullivan, A.J. et al. (1993) Effects of different oral oestrogen formulations on insulin-like growth factor- I, growth hormone and growth hormone binding protein in post-menopausal women. Clinical endocrinology (Oxford), 39, 561-567. (Pubitemid 23323955)
18. Mah, P.M., Webster, J., Jonsson, P. et al. (2005) Estrogen replacement in women of fertile years with hypopituitarism. Journal of Clinical Endocrinology and Metabolism, 90, 5964-5969. (Pubitemid 41606512)
19. Hindmarsh, P.C. (2009) How do you initiate oestrogen therapy in a girl who has not undergone puberty? Clinical endocrinology (Oxford), 71, 7-10.
20. st edn. BMJ Group and Pharmaceutical Press, London, 473-474.
21. Leung, K.C., Doyle, N., Ballesteros, M. et al. (2003) Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proceedings of the National Academy of Sciences of the United States of America, 100, 1016-1021. (Pubitemid 36183947)
22. Fisker, S., Jorgensen, J.O., Vahl, N. et al. (1999) Impact of gender and androgen status on IGF-I levels in normal and GH-deficient adults. European Journal of Endocrinology, 141, 601-608. (Pubitemid 30064760)
23. Christiansen, J.J., Fisker, S., Gravholt, C.H. et al. (2005) Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I. European Journal of Endocrinology, 152, 719-726. (Pubitemid 40744540)
24. Lissett, C.A. & Shalet, S.M. (2003) The impact of dose and route of estrogen administration on the somatotropic axis in normal women. Journal of Clinical Endocrinology and Metabolism, 88, 4668-4672. (Pubitemid 37357509)
25. Friend, K.E., Hartman, M.L., Pezzoli, S.S. et al. (1996) Both oral and transdermal estrogen increase growth hormone release in post-menopausal women-a clinical research center study. Journal of Clinical Endocrinology and Metabolism, 81, 2250-2256. (Pubitemid 26176712)